Health Canada Clears Mounjaro for Pediatric Type 2 Diabetes, Expanding GLP-1 Peptide Use
Eli Lilly Canada says Health Canada approved Mounjaro (tirzepatide) for glycemic control in patients aged 10 to 17 with type 2 diabetes, a first for a once-weekly GIP/GLP-1…
Read article →